• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.与 ACMG SF v2.0 相比,ClinSeq 队列中 ACMG SF v3.0 基因列表使可检出变异的比例提高了 22%。
Genet Med. 2022 Mar;24(3):736-743. doi: 10.1016/j.gim.2021.11.012. Epub 2021 Nov 18.
2
Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.1559 个泰国外显子组中 73 个 ACMG 推荐基因的可操作的次要发现。
J Hum Genet. 2022 Mar;67(3):137-142. doi: 10.1038/s10038-021-00982-2. Epub 2021 Oct 8.
3
Secondary ACMG and non-ACMG genetic findings in a multiethnic cohort of 16,713 pediatric participants.在一个由 16713 名儿科参与者组成的多民族队列中发现次要 ACMG 和非 ACMG 遗传结果。
Genet Med. 2024 Nov;26(11):101225. doi: 10.1016/j.gim.2024.101225. Epub 2024 Jul 31.
4
Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls.在一个大型癌症队列和种族匹配对照中,ACMG 次要发现 v2.0 列表中 24 个癌症基因的致病性/可能致病性变异的流行率。
Genome Med. 2018 Dec 24;10(1):99. doi: 10.1186/s13073-018-0607-5.
5
The rate of secondary genomic findings in the Saudi population.沙特人口中的二级基因组发现率。
Am J Med Genet A. 2022 Jan;188(1):83-88. doi: 10.1002/ajmg.a.62491. Epub 2021 Sep 13.
6
Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.中国人群次要发现的概况:ACMG SF v3.0清单的实践
J Pers Med. 2022 Sep 14;12(9):1503. doi: 10.3390/jpm12091503.
7
Exploring and Expanding Secondary Findings Through Exome Sequencing in the Turkish Population.通过外显子组测序在土耳其人群中探索和扩展次要发现
Ann Hum Genet. 2025 May;89(2-3):106-113. doi: 10.1111/ahg.12592. Epub 2025 Feb 26.
8
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会(ACMG)关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.1清单:一项政策声明
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
9
Secondary findings in 421 whole exome-sequenced Chinese children.421 例全外显子组测序中国儿童的次要发现。
Hum Genomics. 2018 Sep 14;12(1):42. doi: 10.1186/s40246-018-0174-2.
10
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会(ACMG)关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0清单:一项政策声明
Genet Med. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. Epub 2021 May 20.

引用本文的文献

1
ACMG secondary findings in the Brazilian rare genomes project: insights from 5402 genome sequencing.巴西罕见基因组计划中的美国医学遗传学与基因组学学会次要发现:来自5402例基因组测序的见解
J Hum Genet. 2025 May 19. doi: 10.1038/s10038-025-01349-7.
2
Increased risk of kidney failure in patients with genetic kidney disorders.遗传性肾脏疾病患者发生肾衰竭的风险增加。
J Clin Invest. 2024 Sep 3;134(17):e178573. doi: 10.1172/JCI178573.
3
Actionability and familial uptake following opportunistic genomic screening in a pediatric cancer cohort.在儿科癌症队列中进行机会性基因组筛查后的可操作性和家族性接受度。
Eur J Hum Genet. 2024 Jul;32(7):846-857. doi: 10.1038/s41431-024-01618-7. Epub 2024 May 13.
4
Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients.为评估肾移植受者的并发症开发基因检测面板。
Kidney Int. 2024 Jul;106(1):115-125. doi: 10.1016/j.kint.2024.02.021. Epub 2024 Mar 21.
5
Expanding ACMG variant classification guidelines into a general framework.将 ACMG 变异分类指南扩展为通用框架。
Hum Genomics. 2022 Aug 16;16(1):31. doi: 10.1186/s40246-022-00407-x.

本文引用的文献

1
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会(ACMG)关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0清单:一项政策声明
Genet Med. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. Epub 2021 May 20.
2
Management of Secondary Genomic Findings.二级遗传检测结果的管理。
Am J Hum Genet. 2020 Jul 2;107(1):3-14. doi: 10.1016/j.ajhg.2020.05.002.
3
Treatment Options for MODY Patients: A Systematic Review of Literature.青少年发病的成年型糖尿病患者的治疗选择:文献系统综述
Diabetes Ther. 2020 Aug;11(8):1667-1685. doi: 10.1007/s13300-020-00864-4. Epub 2020 Jun 24.
4
The mutational constraint spectrum quantified from variation in 141,456 humans.从 141456 名人类个体的变异中量化的突变约束谱。
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
5
Knowledge, motivations, expectations, and traits of an African, African-American, and Afro-Caribbean sequencing cohort and comparisons to the original ClinSeq cohort.非洲人、非裔美国人和非裔加勒比测序队列的知识、动机、期望和特征,以及与原始 ClinSeq 队列的比较。
Genet Med. 2019 Jun;21(6):1355-1362. doi: 10.1038/s41436-018-0341-9. Epub 2018 Nov 1.
6
Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.解读 ACMG/AMP 失能性预测标准的 PVS1 变异准则的建议。
Hum Mutat. 2018 Nov;39(11):1517-1524. doi: 10.1002/humu.23626. Epub 2018 Sep 7.
7
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.将 ACMG/AMP 变异分类指南建模为贝叶斯分类框架。
Genet Med. 2018 Sep;20(9):1054-1060. doi: 10.1038/gim.2017.210. Epub 2018 Jan 4.
8
ClinVar: improving access to variant interpretations and supporting evidence.ClinVar:改善变异解读和支持证据的获取。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067. doi: 10.1093/nar/gkx1153.
9
Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.扩大基因面板在乳腺癌女性中的应用:乳腺癌风险之外的识别和干预。
Ann Surg Oncol. 2017 Oct;24(10):3060-3066. doi: 10.1245/s10434-017-5963-7. Epub 2017 Aug 1.
10
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.临床外显子组和基因组测序中次要发现报告的建议,2016年更新版(美国医学遗传学与基因组学学会次要发现v2.0):美国医学遗传学与基因组学学会政策声明
Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17.

与 ACMG SF v2.0 相比,ClinSeq 队列中 ACMG SF v3.0 基因列表使可检出变异的比例提高了 22%。

The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.

机构信息

Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; American College of Medical Genetics and Genomics, Bethesda, MD.

出版信息

Genet Med. 2022 Mar;24(3):736-743. doi: 10.1016/j.gim.2021.11.012. Epub 2021 Nov 18.

DOI:10.1016/j.gim.2021.11.012
PMID:34906458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10120277/
Abstract

PURPOSE

The American College of Medical Genetics and Genomics (ACMG) recommends the return of pathogenic and likely pathogenic (P/LP) secondary findings from exome and genome sequencing. The latest version (ACMG secondary finding [SF] v3.0) includes 14 additional genes. We interrogated the ClinSeq cohort for variants in these genes to determine the additional yield in unselected individuals.

METHODS

Exome data from 1473 individuals (60% White, 34% African American or Black, 6% other) were analyzed. We restricted our analyses to coding variants; +1,+2,-1, and -2 splice site variants; and the pathogenic GAA variant, NM_000152.5:c.-32-13T>G. Variants were assessed with slightly modified ACMG/Association of Molecular Pathology guidelines.

RESULTS

A total of 25 P/LP variants were identified. In total, 7 individuals had P/LP variants in genes recommended for return of heterozygous variants, namely HNF1A (1), PALB2 (3), TMEM127 (1), and TTN (2). In total, 4 individuals had a homozygous variant in a gene recommended for biallelic variant return, namely HFE, NM_000410.3(HFE):c.845G>A p.Cys282Tyr. A total of 17 P/LP variants were identified in the heterozygous state in genes recommended only for biallelic variant reporting and were not returned. The frequency of returnable P/LP variants did not significantly differ by race.

CONCLUSION

Using the ACMG SF v3.0, the returnable P/LP variant frequency increased in the ClinSeq cohort by 22%, from 3.4% (n = 50, ACMG SF v2.0) to 4.1% (n = 61, ACMG SF v3.0).

摘要

目的

美国医学遗传学与基因组学学会(ACMG)建议从外显子组和基因组测序中返回致病性和可能致病性(P/LP)的二级发现。最新版本(ACMG 二级发现 [SF] v3.0)包括另外 14 个基因。我们在 ClinSeq 队列中检测了这些基因中的变异,以确定在未选择的个体中额外的检出率。

方法

对 1473 名个体(60%为白人,34%为非裔美国人或黑人,6%为其他种族)的外显子组数据进行了分析。我们将分析仅限于编码变异;+1、+2、-1 和-2 剪接位点变异;以及致病性 GAA 变异,NM_000152.5:c.-32-13T>G。使用稍作修改的 ACMG/分子病理学协会指南评估了变异。

结果

共鉴定出 25 个 P/LP 变异。共有 7 名个体在建议报告杂合变异的基因中携带 P/LP 变异,即 HNF1A(1)、PALB2(3)、TMEM127(1)和 TTN(2)。共有 4 名个体在建议报告双等位基因变异的基因中携带纯合变异,即 HFE,NM_000410.3(HFE):c.845G>A p.Cys282Tyr。共有 17 个 P/LP 变异在仅建议报告双等位基因变异的基因中以杂合状态被检出,但未被报告。可报告的 P/LP 变异的检出率在不同种族之间没有显著差异。

结论

使用 ACMG SF v3.0,ClinSeq 队列中可报告的 P/LP 变异频率增加了 22%,从 ACMG SF v2.0 的 3.4%(n=50)增加到 ACMG SF v3.0 的 4.1%(n=61)。